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Endometrial cancer (EC) is a hormone-dependent cancer that currently represents the most frequent malignancy of the female
reproductive tract. The involvement of steroid hormones in EC etiology and progression has been reported. More recently,
gonadotropins,and,inparticularLH/hCG,areemergingasnovelregulatorsoftumorprogression.Inthepresentreview,wediscuss
the role of the LH/hCG axis (i.e. LH/hCG and its receptors, LH/hCG-R) in both gonadal and nongonadal tissues, in physiological
and neoplastic conditions. In cancer cells, LH/hCG mainly controls cell proliferation and apoptosis. In particular, in EC LH/hCG
improves cell invasiveness, through a mechanism which involves the LH/hCG-R, which in turn activate protein kinase A and
modulate integrin adhesion receptors. Indeed, the LH/hCG-R mRNA is expressed in primary ECs and this expression correlates
withLH/hCG-induced cell invasiveness in vitro.These resultslead to hypothesize thatrecurrent and metastatic ECs,which express
LH/hCG-R,couldbeneﬁtfromtherapiesaimedatdecreasingLHlevels,throughGn-RHanalogues.Hence,theLH/hCGaxiscould
represent a prognostic factor and a new therapeutic target in EC.
1.Introduction
Endometrial cancer (EC) is currently the most frequent
malignancy of the female reproductive tract [1]w i t ha
tendency to increase its incidence during the last decade
[2, 3]. Approximately 75% of EC cases are diagnosed with
the tumor conﬁned to the uterine corpus [2, 3], but after
primary surgery 15% to 20% of these tumors recur and have
limited response to systemic therapy. The most common
basis for determining risk of recurrent disease has been the
categorization of EC into 2 subtypes: type I EC is associated
with good prognosis, low stage and grade, and endometrioid
histology; type II EC is, in contrast, characterized by
high stage and grade, nonendometrioid histology and poor
prognosis. The prognostic value of this distinction is limited,
however, because up to 20% of type I cancer recur, and
half of type II cancers do not [3]. Moreover, the molecular
basis of the distinction between type I and II cancer is
u n d e r s t o o do n l yp a r t i a l l y .T y p eIc a n c e ri sa s s o c i a t e dw i t h
hyperestrogenic risk factors, is more often estrogen and
progesterone receptor positive, microsatellite unstable, and
displays mutations in KRAS or PTEN. Conversely, type II
cancer is more often aneuploid and harbors alterations in
CDKN2A,TP53,andERBB2[4].Suchmolecularalterations,
despite of prognostic value, have not provided a basis for
improved therapy [5].
Hormone (estrogen and progesterone) receptor status
inﬂuences the choice of treatment especially in metastatic
disease. Indeed estrogen secretion, especiallywhenoccurring
withoutprogesteronesecretion,isapparentlyoneofthemost
relevant etiologic factors in EC [6]. In fact, unopposed and
prolonged exposure to estrogens can exert potent mitogenic
eﬀects on the endometrial surface epithelium, thus con-
tributing to the malignant transformation of the latter [7].
However, as stated above, most aggressive tumors are often
receptor negative [2]. In particular, those cancers arising
in the postmenopause, which are often more aggressive,
are also apparently unlinked to estrogen secretion [8]. It2 Obstetrics and Gynecology International
was hypothesized that the latter types of EC might be
sensitivetotheelevatedlevelsofluteinizinghormone/human
chorionic gonadotropin (LH/hCG) that characterize the
post-menopause.
The present review aims at updating the reader about
some current trends in the ﬁeld. In particular, we will focus
on a brief overview of the single elements of the LH/hCG
axis and its relevance in nongonadal tissues in physiological
conditions. Moreover, we will brieﬂy review the role of the
LH/hCG axis in human cancers, with particular emphasis to
EC. Finally, we will provide new perspectives for treatment
of EC based on the targeting of the LH/hCG axis.
2. The LH /hCG Axis:LH/hCG, LH/hCG-R, and
IntracellularSignalling
LH and hCG are structurally related glycoprotein hormones
(GPH) produced by the pituitary gland and placenta, respec-
tively. Both LH and hCG are heterodimers of noncovalently
bound α and β subunits; hCG has a higher molecular
mass and is the most heavily glycosylated among the GPH,
resulting in a longer circulating half-life [9]. LH, secreted by
anterior pituitary gland, is present in all mammalian species.
On the other hand, hCG, which is secreted by placental
trophoblasts, is present exclusively in primates although its
occurrence in other species, as a modiﬁed form, has not
been completely ruled out [10]. These two hormones bind
the same receptors and have similar biological functions,
although hCG is more potent because of its higher receptor
binding aﬃnity and its longer circulatory half life. LH and
hCG are considered the most potent gonadal regulating
hormones, even though there are reports demonstrating
their eﬀects in nongonadal tissues (see below).
The receptor for LH/hCG is encoded by a gene, located
on chromosome 2, position 2p21 [11, 12]. The genomic
sequence of the gene consists of 11 exons separated by
10introns; the transcription of the LH/hCG-R gene can pro-
duce 7 diﬀerent protein-coding mRNAs [12–14]. Recently,
three more alternative splice variants have been found in
corpus luteum and luteinized granulosa cells [14].
The LH/hCG-R is a member of the G-protein coupled
receptor (GPCR) family and its functional activity is medi-
ated by G proteins [6, 15]. The amino acids chain of the
mature LH/hCG-R protein is composed by 699 residues with
a molecular mass of about 78kDa [12, 13]. The protein
consists of a long extracellular N-terminal domain, a region
containing seven transmembrane-spanning sequences con-
nected by alternating extra and intracellular loops, and a
short C-terminal cytoplasmatic tail [13, 16]. The extracellu-
lar domain is characterized by the presence of a structural
motif rich in leucine repeats (LRR) which is involved in
modulating ligand-receptor(s) binding [16].
Such binding determines conformational changes in the
protein structure that in turn induces the activation of
intracellular signalling. In particular, both LH and hCG
stimulate adenylate cyclase on the internal membrane, which
in turn converts adenosine triphosphate (ATP) into cyclic
adenosine monophosphate (cAMP). Cyclic AMP stimulates
the activation of an inactive Protein Kinase A (PKA), which,
besides other actions, stimulates steroidogenesis in the
mitochondria of the target cell by transforming cholesterol
into pregnenolone. Other actions of LH/hCG include the
induction of proteolytic enzymes, prostaglandin synthesis,
inhibin production, induction of 17beta-hydroxysteroid
dehydrogenase, and changes in gene metabolism [17]. LH
and hCG can also trigger the PLC/inositide tris-phosphate
transduction pathway [18, 19]; the cell type and the amount
of the receptor on the plasma membrane can inﬂuence the
prevalent activation of either the signalling pathways [20].
In porcine endometrial cells, the LH hormone activates both
cAMP/PKAandPLC/inositidetris-phosphatepathways[21].
Moreover, LH acting through the Akt and Erk pathways
on theca cells plays a relevant function in vitro and follicle
growth and development [22].
3. Expressionand Role of the LH/hCG Axisin
ExtragonadalTissues
By acting through the transduction mechanisms described
above, LH and hCG regulate ovarian steroidogenesis, but
have also been shown to exert various eﬀects on nongonadal
tissues, such as endometrium, myometrium, and fallopian
tubes.
In the ovary, the main function of GTs is well known.
According to the “two cells-two gonadotropins” theory, LH
isactingonthecacellsduringovarianfolliclegrowth.Atﬁrst,
the synthesis of androgens is induced, then androgens are
transformed in estrogens in the compartment of granulosa
cells through an enzymatic reaction which is dependent on
FSH [23] .B e s i d e so v a r y ,r e c e p t o r sf o rb o t hL Ha n dF S H
were identiﬁed in diﬀerent organs of the female reproductive
apparatus, and in particular in the endometrium [24]. The
presence of LH/hCG-Rs was shown for the ﬁrst time by
Reshef et al. [24] in the uterus of nonpregnant women
by immunohistochemistry, an observation subsequently
conﬁrmed using diﬀerent techniques [25, 26]. Collectively,
LH/hCG-Rs have been identiﬁed in epithelial and stromal
cells of the endometrium as well in smooth muscle cells
of myometrium and uterine vessel. The expression of
LH/hGC-R varied during the women’s cycle phase, with the
maximal expression occurring during the luteal phase, and
a main localization in the luminal and glandular epithelial
cells of endometrium [27]. The attainment of the highest
values of LH/hGC-R correlated, also on a time scale, with
the triggering of cyclo-oxygenase-2 (COX-2) and placental
growth factor (PlGF) production. This ﬁnding suggests the
hypothesis that LH could play a pivotal role at the beginning
of luteolysis [28]. Moreover, LH could regulate the local
metabolism of estrogens and progestins, acting through the
cAMP pathway [29].
Speciﬁc receptors for LH/hCG have also been identiﬁed
in the myometrium of several animal species, including
humans [24].Inthistissue,LH/hCGapparentlyactsthrough
the LH/hCG-R-dependent activation of both the c-AMP
and phospholipase C transduction pathways [20, 21]. It
was proposed that the triggering of adenyl cyclase could
determine an activation of COX-2, which in turn should
induce an increase of the synthesis of either prostaglandinObstetrics and Gynecology International 3
(PG)E, with an ensuing muscle relaxation, or PGF, which
determines the contraction of the uterine musculature [28].
Also in this case, the highest expression of the LH/hCG-R
occurred during the luteal phase of the cycle, and paralleled
an increased synthesis of PGE2.
The LH/hCG-R is also expressed in the internal mucosa
and smooth muscle vascular cells of fallopian tubes [30].
In vitro studies performed on explanted fallopian tissues
showed that LH addition produces a dramatic reduction of
tube motility [31]. This suggests that LH/hCG-R stimulation
could contribute to the quiescent state of tube’s muscles after
ovulation, in turn favouring both oocyte fertilization and
embryo movements along the tube to reach the endometrial
cavity.
4. ExpressionandRoleoftheLH/hCGAxisinEC
Increasing evidence suggests that the action of LH and hCG
might also contribute to the malignant transformation of
human cells, by promoting either promitogenic or anti-
apoptotic eﬀects. For example, LH/hCG-R may be involved
in the progression of some ovarian and breast cancers
[32]. In addition, the expression of LH/hCG-R has been
demonstrated in endometriosis and has been shown to be
increased in patients with adenomyosis [33–35].
Work from Lin et al. [6] showed that the LH/hCG-
R mRNA is also expressed in human ECs, and a notion
subsequently reinforced by the demonstration that the
addition of LH/hCG regulates proliferation in EC cell lines
[7, 36]. In particular, two isoforms of the LH/hCG-R, arising
from alternative splicing of the corresponding gene are
documented in EC samples [37], as well as in neoplastic
ovarian tissues [38]. More recently, we conﬁrmed not only
that speciﬁc LH/hCG-Rs can be detected in human EC, but
also that their expression is apparently related to the cancer
grading [39]. On the basis of these ﬁndings, as well as of
the fact that we determined the eﬀects of LH/hCG in tumor
progression of EC, by analyzing the eﬀects of such GTs on
the invasion potential of both EC cell lines and primary
human EC cells. We showed that human recombinant (hr)
LH (as well as hCG) induced a signiﬁcant increase in cell
invasiveness through Matrigel-coated porous membranes in
thehumanECcelllineHec1A,whichexpressestheLH/hCG-
R. This eﬀect turned out to depend on the hrLH binding to
its speciﬁc receptor and on the following activation of the
cAMP/PKA signaling pathway. Moreover, the hrLH-induced
increase in Hec1A invasiveness was dependent upon the
functional activation of β1 integrin receptors and the sub-
sequent induction of MMP-2 secretion. Interestingly, these
mechanisms were found to be also operative in primary EC
cells transferred in vitro, because hrLH addition produced
an increase in cells invasiveness only in those primary EC
tumors that expressed the LH/hCG-R. Here again, this eﬀect
w a sd e p e n d e n to nP K Aa c t i v i t y[ 40]. Subsequently, we also
provided evidence that the LH/hCG-R mRNA is expressed
in the great majority of a cohort of primary ECs and that
cells obtained from primary ECs can be triggered to invade
a Matrigel layer by LH addition. A good correlation was
found between the level of LH/hCG-R mRNA expressed by
primary EC andthatofLH-inducedcellinvasiveness invitro.
T h ea n a l y s i so fc e l li n v a s i o nin vitro in response to LH/hCG,
allowed us to divide the EC samples into two groups, one
witha null or verylow response (non-responders = NR)and
the other with a signiﬁcant response to LH (responders =
R). The two groups had signiﬁcantly diﬀerent levels of
LH/hCG-R mRNA expression. These results may contribute
to reconcile the conﬂicting results present in the literature,
about the clinical eﬀect of LH analogues in the treatment of
recurrent or metastatic EC (see below).
On the whole, these results open the possibility that GTs
coulddirectlyregulatetumorprogressionofECbyregulating
tumor invasiveness through the binding to speciﬁc receptors
exposed on the plasma membrane of EC. This ﬁnding opens
new therapeutic prospective of recurrent EC.
5. Therapeutical Perspectives
Some clinical trials were performed with the aim of treating
patients aﬀected by EC with Gonadotropin releasing hor-
mone (Gn-RH) analogues, in order to decrease LH levels.
Conﬂicting results emerged from these studies. In fact,
Davies et al. [36], Lhomm´ e et al. [41], and Jeyarajah et al.
[42] showed evidence of eﬃcacy in long-term treatments,
with response rate ranging from 9% to 57%. On the other
hand, Covens et al. [43], Markman et al. [44], and Asbury
et al. [45] observed insuﬃcient activity. We provided a
contribution in this controversy, reporting a case of a patient
aﬀected by EC, primarily treated with a Gn-RH analogue. In
fact, in this case, surgical treatment was unfeasible, due to
the compromised health of the patient [46]. The therapy was
carried out for 6 years and no progression of the disease was
observed throughout this period.
Our recent data, reported in the previous paragraph,
on the role of LH/hCG in EC invasiveness could contribute
to reconcile the conﬂicting results present in the literature,
about the clinical eﬀect of LH analogues in the treatment
of recurrent or metastatic EC. In fact we showed that only
35%ofpatientsshowedahighexpressionofLH/hCGmRNA
andonlythesepatientsrespondedtoexogenousrecombinant
LH addition by increasing the cell invasion through Matrigel
[39]. This could in turn imply that only patients highly
positive for LH/hCG-R expression could receive beneﬁts
from a therapy aimed at decreasing LH levels, through Gn-
RH analogues. On the whole, based on available data, we
suggest that therapies, employing Gn-RH analogues, could
produce beneﬁts in the treatment of recurrent or metastatic
EC, especially in those patients where cancer tissue displays
high LH/hCG-R levels. We prospect to analyze herein all the
IV stage patients (whose ﬁve-year survival is less than 10%)
for the expression of LH/hCG mRNA and treat only the high
expressors with Gn-RH analogues.
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